浙江钱江生物化学股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 证券代码：600796 证券简称：钱江生化 公告编号：临 2025-054 （一）会议召开时间：2025年11月18日（星期二）10:00-11:00 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 11 日 （星期二） 至 11 月 17 日 （星 期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目 或通过公司邮箱 qjbioch@600796.com 进行提问。公司将在说明会上 对投资者普遍关注的问题进行回答。 浙江钱江生物化学股份有限公司（以下简称"公司"）已于 2025 年 10 月 28 日发布公司 2025 年第三季度报告，为便于广大投资者更 全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计 划于 2025 年 11 月 18 日 （星期二） 10:00-1 ...

Core Viewpoint - The company is actively involved in the "Vanguard" and "Leading Goose" projects in Zhejiang Province, focusing on the development and application of plant growth-promoting bacteria and related stimulants, which aims to enhance soil improvement and profitability [1] Group 1 - The project aims to develop plant growth-promoting bacteria products for soil improvement, expanding the company's product offerings into the soil enhancement sector [1] - The company has completed the development of a high-concentration gibberellic acid soluble agent and one microbial agent, with samples delivered [1] - The microbial fertilizer has entered the registration process, with an expected registration certificate by 2026 [1]

Group 1 - The core viewpoint of the news is the initiation of large-scale clinical trials for gene-edited pig kidneys for human transplantation, marking a significant advancement in biotechnology and organ transplantation [1] - The first clinical trial was completed at NYU Langone Medical Center, approved by the FDA, aiming to evaluate the safety and efficacy of gene-edited pig kidneys for patients with end-stage kidney disease [1] - Global advancements in gene editing technology have been reported, including successful transplantation of gene-edited pig lungs in China and new treatment approaches for Down syndrome in Japan [1] Group 2 - Huazhong Securities highlights that breakthroughs in gene editing technology have significantly lowered the technical barriers for genetic modification, enabling large-scale industrial production of drugs [2] - In the A-share market, there are 22 listed companies with gene editing technology reserves, with mixed performance in stock prices; only 7 out of 22 companies saw gains on November 5 [4] - Among gene editing concept stocks, Shuanglu Pharmaceutical reported the highest net profit of 141 million yuan in the first three quarters, while Mengcao Ecological achieved a year-on-year profit increase of 48.73% [5][6] Group 3 - Eight gene editing concept stocks received attention from five or more institutions, with companies like Sturdy Medical and Huaxi Biological leading in institutional ratings [7] - Sturdy Medical announced a collaboration with Huazhong Agricultural University to establish a cotton research institute, focusing on gene editing and hybridization techniques for cotton seed improvement [7]

Group 1 - The core point of the news is the initiation of large-scale clinical trials for gene-edited pig kidneys for human transplantation, marking a significant breakthrough in gene editing technology [1] - The trials are approved by the FDA and aim to systematically evaluate the safety and efficacy of gene-edited pig kidneys for patients with end-stage kidney disease [1] - There have been multiple advancements in gene editing technology globally, including successful transplants of gene-edited organs and new treatment approaches for genetic disorders [1] Group 2 - Huazhong Securities notes that breakthroughs in gene editing technology have significantly lowered the technical barriers for genetic modification, enabling large-scale industrial production and reducing drug production costs [2] - A total of 22 listed companies in the A-share market have gene editing technology reserves, with several companies reporting profitability in their third-quarter results [3] - Notable companies include Shuanglu Pharmaceutical, which reported a net profit of 141 million yuan, and Mengcao Ecological, which saw a 48.73% year-on-year increase in net profit [3][4] Group 3 - Companies like Wanjian Medical are collaborating with research institutions to develop cotton varieties using gene editing technology, indicating the application of gene editing beyond human health [5] - The number of institutional ratings for gene editing concept stocks shows significant interest, with companies like Wanjian Medical and Huaxi Biological receiving the highest number of ratings [6]

Core Insights - The environmental governance sector saw an increase of 0.81% on November 3, with Zhejiang Fu Holdings leading the gains [1] - The Shanghai Composite Index closed at 3976.52, up 0.55%, while the Shenzhen Component Index closed at 13404.06, up 0.19% [1] Environmental Governance Sector Performance - Top gainers included: - Zhejiang Fu Holdings (002266) with a closing price of 4.52, up 9.98% and a trading volume of 1.93 million shares, totaling 873 million yuan [1] - Zhonghuan Environmental (300692) at 9.58, up 7.28% with a trading volume of 450,900 shares, totaling 434 million yuan [1] - Haitan Co., Ltd. (603759) at 11.74, up 6.73% with a trading volume of 370,700 shares, totaling 413 million yuan [1] - Other notable gainers included: - Feima International (002210) at 4.45, up 5.95% with a trading volume of 6.29 million shares, totaling 2.83 billion yuan [1] - ST New Power (300152) at 2.50, up 5.49% with a trading volume of 374,000 shares, totaling 9.19 million yuan [1] Fund Flow Analysis - The environmental governance sector experienced a net outflow of 772 million yuan from institutional investors, while retail investors saw a net inflow of 677 million yuan [2] - The top stocks by fund flow included: - Zhejiang Fu Holdings (002266) with a net inflow of 22.3 million yuan from institutional investors, but a net outflow of 114 million yuan from speculative funds [3] - Feima International (002210) with a net inflow of 10.7 million yuan from institutional investors, but a net outflow of 97.8 million yuan from speculative funds [3] - Yuan Da Environmental (600292) with a net inflow of 38.3 million yuan from institutional investors, but a net outflow of 14.9 million yuan from speculative funds [3]

特此公告。 浙江钱江生物化学股份有限公司董事会 2025 年 11 月 1 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江钱江生物化学股份有限公司（以下简称"公司"）工会联合会委员会于 近日召开了 2025 年第二次代表大会，审议并通过《关于监事会不再设立后职工 监事不再任职的议案》。根据《中华人民共和国公司法》、中国证券监督管理委 员会《关于新<公司法>配套制度规则实施相关过渡期安排》《公司章程》等法律 法规、监管制度的相关要求，结合公司实际情况，公司不再设立监事会，现任职 工监事朱炳其先生自监事会正式撤销之日起不再担任职工监事。上述调整自公司 《关于增加经营范围、取消监事会并修订<公司章程>的议案》经公司股东大会审 议通过后生效。 证券代码：600796 股票简称：钱江生化 编号：临 2025—053 浙江钱江生物化学股份有限公司 关于监事会不再设立后职工监事不再任职的公告 ...

证券代码：600796 证券简称：钱江生化 公告编号：2025-051 浙江钱江生物化学股份有限公司 2025年第四次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 10 月 31 日 (二)股东大会召开的地点：浙江省海宁市海洲街道钱江西路 178 号钱江大厦本公 司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 169 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 657,496,952 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 75.8721 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，现场会议由公司董事长朱燕刚先生主持，会议 采用现场投票和网络投票相结合的方式表决通 ...

重要内容提示： 一、董事会会议召开情况 浙江钱江生物化学股份有限公司（以下简称"公司"）十届董事会 2025 年第 七次临时会议于 2025 年 10 月 31 日在公司会议室以现场和通讯相结合方式召开。 会议通知于 2025 年 10 月 23 日以书面及电子邮件方式发出。会议应到董事九名, 实到董事九名，董事钱宏声先生以通讯方式表决，高管列席了会议。会议由公司 董事长朱燕刚先生主持，本次会议的召开符合《公司法》及《公司章程》的规定。 证券代码：600796 股票简称：钱江生化 编号：临 2025-052 浙江钱江生物化学股份有限公司 十届董事会 2025 年第七次临时会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 二、董事会会议审议情况 （一）审议通过了《关于选举代表公司执行公司事务的董事的议案》； 表决结果：9 票同意、0 票反对、0 票弃权。 本议案无需提交公司股东大会审议。 公司取消监事会后，由审计委员会行使《公司法》规定的监事会的职权，本次董 事会确认公司第十届董事会审计委员会仍由张广冬先生、韦 ...

法律意见书 上海市锦天城律师事务所 关于浙江钱江生物化学股份有限公司 2025 年第四次临时股东大会的 锦 天 城 律师事务 所 ALLBRIGHT LAW OFFICES 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 电话:021-20511000 邮编：200120 t on the state of the state of the state of the station of the status and the stat use alled the sin the successful hour 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于浙江钱江生物化学股份有限公司 2025 年第四次临时股东大会的 法律意见书 致：浙江钱江生物化学股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受浙江钱江生物化学股份 有限公司（以下简称"公司"）委托，就公司召开 2025 年第四次临时股东大会 （以下简称"本次股东大会"）的有关事宜，根据《中华人民共和国公司法》（以 下简称《公司法》）、《上市公司股东会规则》等法律法规、规章和其他规范性 文件以及《浙江钱 ...

Group 1 - The company Qianjiang Biochemical (SH 600796) held its 10th Board of Directors' temporary meeting on October 31, 2025, to review various proposals, including the confirmation of the Audit Committee members and the convener [1] - For the fiscal year 2024, the revenue composition of Qianjiang Biochemical is as follows: wastewater treatment and recycling at 28.2%, engineering installation and material sales at 22.76%, waste clearance and disposal at 18.53%, biological products at 14.5%, thermal power at 9.85%, and water treatment and supply at 5.43% [1] - As of the report date, Qianjiang Biochemical has a market capitalization of 5.5 billion yuan [1]